KR102418413B1 - 결핵의 치료를 위한 헤테로바이사이클릭 화합물 및 이들의 용도 - Google Patents

결핵의 치료를 위한 헤테로바이사이클릭 화합물 및 이들의 용도 Download PDF

Info

Publication number
KR102418413B1
KR102418413B1 KR1020177007855A KR20177007855A KR102418413B1 KR 102418413 B1 KR102418413 B1 KR 102418413B1 KR 1020177007855 A KR1020177007855 A KR 1020177007855A KR 20177007855 A KR20177007855 A KR 20177007855A KR 102418413 B1 KR102418413 B1 KR 102418413B1
Authority
KR
South Korea
Prior art keywords
fluoro
methoxy
compound
chloro
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177007855A
Other languages
English (en)
Korean (ko)
Other versions
KR20170043644A (ko
Inventor
히로시 시미즈
요시카즈 가와노
슌페이 이시카와
šœ페이 이시카와
유키타카 우에마츠
도시오 시노하라
모토히로 이토타니
요시카즈 하라구치
이사오 다케무라
아츠노리 가네시게
유야 나카이
노리미츠 하리구치
요헤이 하야시
마코토 마츠모토
Original Assignee
오쓰까 세이야꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54105947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102418413(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 오쓰까 세이야꾸 가부시키가이샤 filed Critical 오쓰까 세이야꾸 가부시키가이샤
Publication of KR20170043644A publication Critical patent/KR20170043644A/ko
Application granted granted Critical
Publication of KR102418413B1 publication Critical patent/KR102418413B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y10S514/924—

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
KR1020177007855A 2014-08-28 2015-08-28 결핵의 치료를 위한 헤테로바이사이클릭 화합물 및 이들의 용도 Active KR102418413B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2014-174528 2014-08-28
JP2014174528 2014-08-28
PCT/JP2015/004371 WO2016031255A1 (en) 2014-08-28 2015-08-28 Heterobicyclic compounds and their use for the treatment of tuberculosis

Publications (2)

Publication Number Publication Date
KR20170043644A KR20170043644A (ko) 2017-04-21
KR102418413B1 true KR102418413B1 (ko) 2022-07-06

Family

ID=54105947

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177007855A Active KR102418413B1 (ko) 2014-08-28 2015-08-28 결핵의 치료를 위한 헤테로바이사이클릭 화합물 및 이들의 용도

Country Status (29)

Country Link
US (2) US10053446B2 (enExample)
EP (1) EP3186240B9 (enExample)
JP (1) JP6625612B2 (enExample)
KR (1) KR102418413B1 (enExample)
CN (1) CN106795117B (enExample)
AP (1) AP2017009788A0 (enExample)
AR (1) AR101704A1 (enExample)
AU (1) AU2015307873B2 (enExample)
BR (1) BR112017003231B1 (enExample)
CA (1) CA2959478C (enExample)
CY (1) CY1122286T1 (enExample)
DK (1) DK3186240T3 (enExample)
EA (1) EA038414B1 (enExample)
ES (1) ES2743788T3 (enExample)
HR (1) HRP20191486T2 (enExample)
HU (1) HUE045025T2 (enExample)
IL (1) IL250484B (enExample)
LT (1) LT3186240T (enExample)
MX (1) MX2017002312A (enExample)
MY (1) MY189098A (enExample)
NZ (1) NZ729064A (enExample)
PH (1) PH12017500290B1 (enExample)
PL (1) PL3186240T3 (enExample)
PT (1) PT3186240T (enExample)
SG (1) SG11201700882XA (enExample)
SI (1) SI3186240T1 (enExample)
TW (1) TWI687409B (enExample)
WO (1) WO2016031255A1 (enExample)
ZA (1) ZA201700916B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI687409B (zh) * 2014-08-28 2020-03-11 日商大塚製藥股份有限公司 稠合雜環化合物
US10851079B2 (en) 2016-02-26 2020-12-01 Otsuka Pharmaceutical Co., Ltd. Piperidine derivative
CN112543757A (zh) 2018-06-15 2021-03-23 卡迪拉保健有限公司 对结核菌具有抗菌活性的缩合氮杂杂芳基化合物
JP2023085582A (ja) * 2020-05-11 2023-06-21 大塚製薬株式会社 ジヒドロキノリノン化合物の共結晶
WO2022039506A1 (ko) * 2020-08-19 2022-02-24 주식회사 미토이뮨테라퓨틱스 Ｍabc-r 감염에 의한 병적 염증 치료제로서의 미토콘드리아 표적 항산화제
CN116102537B (zh) * 2021-11-10 2024-10-01 四川大学 一种喹啉酮类衍生物及其制备方法和用途
CN116589448B (zh) * 2023-04-24 2025-10-28 西南交通大学 一种3,4-二氢喹啉酮衍生物及其应用
WO2025183016A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物
WO2025183017A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042542A1 (en) 2003-10-31 2005-05-12 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis
WO2010004347A1 (en) 2008-07-10 2010-01-14 Prosidion Limited Heterocyclic gpcr agonists
WO2010045987A1 (en) 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
AR041198A1 (es) 2002-10-11 2005-05-04 Otsuka Pharma Co Ltd Compuesto 2,3-dihidro-6-nitroimidazo[2,1-b] oxaxol, y composiciones farmaceuticas que lo contienen
GB0319150D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
JP4761756B2 (ja) 2003-10-31 2011-08-31 大塚製薬株式会社 ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
CN100497345C (zh) * 2003-10-31 2009-06-10 大塚制药株式会社 治疗结核病的2,3-二氢-6-硝基咪唑并[2,1-b]唑化合物
CA2881078C (en) * 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
NZ598165A (en) 2009-07-31 2013-05-31 Global Alliance For Tb Drug Dev Nitroimidazooxazine and nitroimidazooxazole analogues and their uses
US9051333B2 (en) 2011-04-15 2015-06-09 Otsuka Pharmaceutical Co., Ltd. 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides
TWI687409B (zh) * 2014-08-28 2020-03-11 日商大塚製藥股份有限公司 稠合雜環化合物
US10851079B2 (en) * 2016-02-26 2020-12-01 Otsuka Pharmaceutical Co., Ltd. Piperidine derivative

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042542A1 (en) 2003-10-31 2005-05-12 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis
WO2010004347A1 (en) 2008-07-10 2010-01-14 Prosidion Limited Heterocyclic gpcr agonists
WO2010045987A1 (en) 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials

Also Published As

Publication number Publication date
NZ729064A (en) 2022-09-30
PH12017500290B1 (en) 2023-07-19
US10053446B2 (en) 2018-08-21
ZA201700916B (en) 2019-06-26
HRP20191486T2 (hr) 2021-09-17
CN106795117A (zh) 2017-05-31
SG11201700882XA (en) 2017-03-30
MX2017002312A (es) 2017-05-08
JP6625612B2 (ja) 2019-12-25
PL3186240T3 (pl) 2020-03-31
TWI687409B (zh) 2020-03-11
ES2743788T3 (es) 2020-02-20
IL250484A0 (en) 2017-03-30
CN106795117B (zh) 2020-06-26
PH12017500290A1 (en) 2017-06-28
KR20170043644A (ko) 2017-04-21
EP3186240B1 (en) 2019-06-12
MY189098A (en) 2022-01-25
US10464926B2 (en) 2019-11-05
LT3186240T (lt) 2019-09-10
US20180312488A1 (en) 2018-11-01
US20170253576A1 (en) 2017-09-07
CA2959478C (en) 2023-09-26
PT3186240T (pt) 2019-09-06
SI3186240T1 (sl) 2019-10-30
AP2017009788A0 (en) 2017-02-28
AU2015307873A1 (en) 2017-03-09
DK3186240T3 (da) 2019-08-26
EP3186240A1 (en) 2017-07-05
HUE045025T2 (hu) 2019-12-30
AU2015307873B2 (en) 2020-01-16
AR101704A1 (es) 2017-01-04
TW201609658A (zh) 2016-03-16
EA201790464A1 (ru) 2017-06-30
WO2016031255A1 (en) 2016-03-03
BR112017003231B1 (pt) 2022-10-11
EP3186240B9 (en) 2019-12-04
IL250484B (en) 2020-04-30
CA2959478A1 (en) 2016-03-03
EA038414B1 (ru) 2021-08-25
HRP20191486T1 (hr) 2019-11-15
CY1122286T1 (el) 2021-01-27
BR112017003231A2 (pt) 2017-11-28
JP2017525697A (ja) 2017-09-07

Similar Documents

Publication Publication Date Title
US10464926B2 (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
TWI894229B (zh) 作為yap/taz-tead蛋白-蛋白相互作用抑制劑之聯芳基衍生物
US20120225062A1 (en) Novel kinase inhibitors
TWI873165B (zh) (雜)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
UA110841C2 (uk) СПОЛУКИ ТА КОМПОЗИЦІЇ ЯК ІНГІБІТОРИ с-KІТ КІНАЗИ
JP2024529181A (ja) ピラゾロピリジノン化合物
CA2927182A1 (en) Quinolinyl modulators of ror.gamma.t
JP2008515796A (ja) 新規なピペリジン系抗生物質
EP3421454B9 (en) Piperidine derivative
US20080275035A1 (en) Nitroimidazole Compounds
JP6976691B2 (ja) 医薬組成物
JP7390728B2 (ja) 抗菌複素環式化合物及びそれらの合成
OA18228A (en) Heterobicyclic compounds and their use for the treatment of tuberculosis.
HK1239683A1 (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
HK1239683B (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
EA047452B1 (ru) Биарильные производные в качестве ингибиторов белок-белкового взаимодействия yap/taz-tead
MX2008008195A (en) Nitroimidazole compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5